Largest positions
| Issuer | Class | Value | Share |
|---|---|---|---|
| Praxis Precision Medicines ICOM NEW | COM NEW | $681,627,753 | 10.2% |
| Spyre Therapeutics Inc.COM NEW | COM NEW | $383,484,855 | 5.8% |
| Celcuity Inc.COM | COM | $334,491,064 | 5.0% |
| Ascendis Pharma A/sORD SHS | ORD SHS | $310,387,665 | 4.7% |
| Rhythm Pharmaceuticals Inc.COM | COM | $287,156,334 | 4.3% |
| Roivant Sciences LtdSHS | SHS | $286,144,465 | 4.3% |
| Relay Therapeutics Inc.COM | COM | $263,926,759 | 4.0% |
| Travere Therapeutics Inc.COM | COM | $213,183,729 | 3.2% |
| Kardigan Inc.COM | COM | $195,585,788 | 2.9% |
| Nuvalent Inc.COM | COM | $195,192,368 | 2.9% |
| Edgewise Therapeutics Inc.COM | COM | $177,714,564 | 2.7% |
| Apogee Therapeutics Inc.COM | COM | $173,625,838 | 2.6% |
| Amylyx Pharmaceuticals Inc.COM | COM | $149,694,481 | 2.2% |
| Meiragtx Hldgs PLCCOM | COM | $145,727,749 | 2.2% |
| Oruka Therapeutics Inc.COM | COM | $128,009,646 | 1.9% |
| Inhibrx Biosciences Inc.COM | COM | $122,963,044 | 1.8% |
| Protagonist Therapeutics Inc.COM | COM | $120,358,728 | 1.8% |
| Solid Biosciences Inc.COM NEW | COM NEW | $118,947,393 | 1.8% |
| Zymeworks Inc.COM | COM | $109,342,391 | 1.6% |
| Tango Therapeutics Inc.COM | COM | $105,565,020 | 1.6% |
| Immatics N.vSHS | SHS | $105,184,409 | 1.6% |
| Nurix Therapeutics Inc.COM | COM | $104,813,438 | 1.6% |
| Biocryst Pharmaceuticals Inc.COM | COM | $103,088,880 | 1.5% |
| Revolution Medicines Inc.COM | COM | $98,808,928 | 1.5% |
| Avalyn Pharmaceuticals Inc.COM SHS | COM SHS | $88,070,744 | 1.3% |
| Moderna Inc. (put option)COM | COM | $70,030,000 | 1.1% |
| Dyne Therapeutics Inc.COM | COM | $59,727,909 | 0.9% |
| Biogen Inc.COM | COM | $59,669,938 | 0.9% |
| Immunovant Inc.COM | COM | $52,299,967 | 0.8% |
| Unitedhealth Group Inc.COM | COM | $48,548,078 | 0.7% |
| SPDR Series Trust (put option)ST STR SP BIOT | ST STR SP BIOT | $47,475,000 | 0.7% |
| Ionis Pharmaceuticals Inc.COM | COM | $44,878,140 | 0.7% |
| Sutro Biopharma Inc.COM SHS | COM SHS | $43,320,887 | 0.7% |
| Alto Neuroscience Inc.COM SHS | COM SHS | $42,485,076 | 0.6% |
| Jazz Pharmaceuticals PLCSHS USD | SHS USD | $40,964,900 | 0.6% |
| Corvus Pharmaceuticals Inc.COM | COM | $39,851,569 | 0.6% |
| Sionna Therapeutics Inc.COM | COM | $39,810,950 | 0.6% |
| Cytomx Therapeutics Inc..COM | COM | $39,146,944 | 0.6% |
| Artivion Inc.COM | COM | $39,036,906 | 0.6% |
| X4 Pharmaceuticals Inc.COM NEW | COM NEW | $37,049,403 | 0.6% |
| Corcept Therapeutics Inc.COM | COM | $34,639,576 | 0.5% |
| Repligen Corp.COM | COM | $33,866,045 | 0.5% |
| Anteris Technologies GlobalCOM | COM | $33,740,939 | 0.5% |
| Rapport Therapeutics Inc.COM | COM | $32,225,161 | 0.5% |
| Damora Therapeutics Inc.COM NEW | COM NEW | $31,810,230 | 0.5% |
| Charles Riv Labs Intl Inc.COM | COM | $31,750,600 | 0.5% |
| Axsome Therapeutics Inc..COM | COM | $28,993,007 | 0.4% |
| Eyepoint Inc. (put option)COM NEW | COM NEW | $28,600,000 | 0.4% |
| Dbv Technologies S ASPONSORED ADS | SPONSORED ADS | $27,114,940 | 0.4% |
| Irhythm Holdings Inc.COM | COM | $26,616,966 | 0.4% |
Praxis Precision Medicines ICOM NEW$681,627,753
- Class
- COM NEW
- Share
- 10.2%
Spyre Therapeutics Inc.COM NEW$383,484,855
- Class
- COM NEW
- Share
- 5.8%
Celcuity Inc.COM$334,491,064
- Class
- COM
- Share
- 5.0%
Ascendis Pharma A/sORD SHS$310,387,665
- Class
- ORD SHS
- Share
- 4.7%
Rhythm Pharmaceuticals Inc.COM$287,156,334
- Class
- COM
- Share
- 4.3%
Roivant Sciences LtdSHS$286,144,465
- Class
- SHS
- Share
- 4.3%
Relay Therapeutics Inc.COM$263,926,759
- Class
- COM
- Share
- 4.0%
Travere Therapeutics Inc.COM$213,183,729
- Class
- COM
- Share
- 3.2%
Kardigan Inc.COM$195,585,788
- Class
- COM
- Share
- 2.9%
Nuvalent Inc.COM$195,192,368
- Class
- COM
- Share
- 2.9%
Edgewise Therapeutics Inc.COM$177,714,564
- Class
- COM
- Share
- 2.7%
Apogee Therapeutics Inc.COM$173,625,838
- Class
- COM
- Share
- 2.6%
Amylyx Pharmaceuticals Inc.COM$149,694,481
- Class
- COM
- Share
- 2.2%
Meiragtx Hldgs PLCCOM$145,727,749
- Class
- COM
- Share
- 2.2%
Oruka Therapeutics Inc.COM$128,009,646
- Class
- COM
- Share
- 1.9%
Inhibrx Biosciences Inc.COM$122,963,044
- Class
- COM
- Share
- 1.8%
Protagonist Therapeutics Inc.COM$120,358,728
- Class
- COM
- Share
- 1.8%
Solid Biosciences Inc.COM NEW$118,947,393
- Class
- COM NEW
- Share
- 1.8%
Zymeworks Inc.COM$109,342,391
- Class
- COM
- Share
- 1.6%
Tango Therapeutics Inc.COM$105,565,020
- Class
- COM
- Share
- 1.6%
Immatics N.vSHS$105,184,409
- Class
- SHS
- Share
- 1.6%
Nurix Therapeutics Inc.COM$104,813,438
- Class
- COM
- Share
- 1.6%
Biocryst Pharmaceuticals Inc.COM$103,088,880
- Class
- COM
- Share
- 1.5%
Revolution Medicines Inc.COM$98,808,928
- Class
- COM
- Share
- 1.5%
Avalyn Pharmaceuticals Inc.COM SHS$88,070,744
- Class
- COM SHS
- Share
- 1.3%
Moderna Inc. (put option)COM$70,030,000
- Class
- COM
- Share
- 1.1%
Dyne Therapeutics Inc.COM$59,727,909
- Class
- COM
- Share
- 0.9%
Biogen Inc.COM$59,669,938
- Class
- COM
- Share
- 0.9%
Immunovant Inc.COM$52,299,967
- Class
- COM
- Share
- 0.8%
Unitedhealth Group Inc.COM$48,548,078
- Class
- COM
- Share
- 0.7%
SPDR Series Trust (put option)ST STR SP BIOT$47,475,000
- Class
- ST STR SP BIOT
- Share
- 0.7%
Ionis Pharmaceuticals Inc.COM$44,878,140
- Class
- COM
- Share
- 0.7%
Sutro Biopharma Inc.COM SHS$43,320,887
- Class
- COM SHS
- Share
- 0.7%
Alto Neuroscience Inc.COM SHS$42,485,076
- Class
- COM SHS
- Share
- 0.6%
Jazz Pharmaceuticals PLCSHS USD$40,964,900
- Class
- SHS USD
- Share
- 0.6%
Corvus Pharmaceuticals Inc.COM$39,851,569
- Class
- COM
- Share
- 0.6%
Sionna Therapeutics Inc.COM$39,810,950
- Class
- COM
- Share
- 0.6%
Cytomx Therapeutics Inc..COM$39,146,944
- Class
- COM
- Share
- 0.6%
Artivion Inc.COM$39,036,906
- Class
- COM
- Share
- 0.6%
X4 Pharmaceuticals Inc.COM NEW$37,049,403
- Class
- COM NEW
- Share
- 0.6%
Corcept Therapeutics Inc.COM$34,639,576
- Class
- COM
- Share
- 0.5%
Repligen Corp.COM$33,866,045
- Class
- COM
- Share
- 0.5%
Anteris Technologies GlobalCOM$33,740,939
- Class
- COM
- Share
- 0.5%
Rapport Therapeutics Inc.COM$32,225,161
- Class
- COM
- Share
- 0.5%
Damora Therapeutics Inc.COM NEW$31,810,230
- Class
- COM NEW
- Share
- 0.5%
Charles Riv Labs Intl Inc.COM$31,750,600
- Class
- COM
- Share
- 0.5%
Axsome Therapeutics Inc..COM$28,993,007
- Class
- COM
- Share
- 0.4%
Eyepoint Inc. (put option)COM NEW$28,600,000
- Class
- COM NEW
- Share
- 0.4%
Dbv Technologies S ASPONSORED ADS$27,114,940
- Class
- SPONSORED ADS
- Share
- 0.4%
Irhythm Holdings Inc.COM$26,616,966
- Class
- COM
- Share
- 0.4%
The share class is shown on a wider screen.
The 50 largest of 109 positions by value, with holdings of the same security combined. The 109 largest are in this firm's machine-readable record. Share counts and quarter-on-quarter changes for each position are on EDGAR. View the full information table on EDGAR
This filing
- Form
- 13F-HR
- CIK
- 1224962
- File number
- 028-10438
- Options
- 1 call, 6 put
- In the 25 largest
- 75.1%
- Prior quarter
- $5,117,574,591 at 31 March 2026
- Positions opened
- 29
- Positions closed
- 14
Common questions
What are Perceptive Advisors’ 13F holdings worth?
$6,661,817,069 across 109 positions for the quarter ended 30 June 2026.
What is Perceptive Advisors’ largest 13F holding?
PRAXIS PRECISION MEDICINES I (COM NEW) was the largest position at $681,627,753, or 10.2% of reported 13F value, as of 30 June 2026.
How concentrated is Perceptive Advisors’ 13F portfolio?
The ten largest positions accounted for 47.3% of reported value and the twenty-five largest for 75.1%, across 109 positions as of 30 June 2026.
Does Form 13F show everything Perceptive Advisors manages?
No. Form 13F covers only long positions in exchange-traded securities over which the manager has investment discretion, valued at quarter end. It excludes cash, most bonds, private funds, and any assets the firm does not have discretion over, so it is neither the firm's total assets nor any individual client's portfolio.
How often does Perceptive Advisors file its 13F?
Every quarter. Managers file within 45 days of each quarter's end, so the figures are a snapshot that changes between filings. This page shows the quarter ended 30 June 2026.
Answered from this filing and the prior quarter's.